TO THE EDITOR
The notion that gene silencing after methylation of promoters of tumor suppresser genes results in carcinogenesis is supported by many lines of evidence. Myelodysplastic syndrome (MDS) is a stem cell disorder that is characterized by frequent evolution to acute myelogenous leukemia. We found that aberrant methylation of the promoter region of the p15 INK4B gene is frequent in MDS, that this plays an important role in clonal expansion in MDS and that it might be related to disease progression. 1 We also reported that the p15 INK4B gene is methylated not only in the blast population, but also in differentiated cells among MDS patients, suggesting that p15 INK4B methylation is an early event in MDS. 2, 3 However, the molecular mechanism(s) responsible for aberrant methylation of the p15 INK4B gene in MDS remains obscure.
DNA methyltransferases (DNMT) are the enzymes responsible for DNA methylation and DNMTs 1, 3a and 3b have been identified in vivo. Levels of DNMT1 activities are high in many cultured tumor cell lines. 4 However, the results of studies analyzing the expression levels or total DNA methyltransferase activity in human cancers are contradictory. [5] [6] [7] [8] Among hematological malignancies, all three DNMTs are overexpressed in acute myelogenous leukemia (AML) and the acute phase of chronic myelogenous leukemia (CML). Furthermore, the expression levels of DNMTs are higher in AML patients with, than without methylated p15 INK4B . 9 The present study uses real-time quantitative RT-PCR to determine whether individual expression levels of DNMTs correlate with aberrant methylation of the p15 INK4B gene in patients with MDS.
We analyzed seven lymphoid and eight myeloid leukemia/ lymphoma cell lines and bone marrow mononuclear cells (BM-MNC) obtained from 24 MDS patients (refractory anemia (RA), 7; RA with ring sideroblasts (RARS), 2; RA with excess blasts (RAEB), 5; RAEB in transformation (RAEB-T), 5; chronic myelomonocytic leukemia (CMML), 3 and secondary myelogenous leukemia (sAML), 2). We also evaluated BM-MNC from 10 patients with nonHodgkin's lymphoma (NHL) whose disease did not involve BM, as normal controls. All samples were obtained with the written informed consent of the patients. We extracted DNA and total RNA from cell lines and BM-MNCs using standard procedures and methylation-specific PCR (MSP) detected p15
INK4B gene methylation as described. 2 Real-time quantitative RT-PCR evaluated expression levels of DNMT1, 3a, 3b mRNA. We prepared first-strand cDNA from 5 mg of total cellular RNA using a random hexadeoxynucleotide primer and M-MLV reverse transcriptase 0 for DNMT3b. To standardize the integrity of RNA, the efficiency of the RT-PCR and the amount of applied RNA, we amplified glyceraldehyde phosphate dehydrogenase (GAPDH) mRNA using the GAPDH control Reagent kit (PE Applied Biosystems, Foster City, CA, USA) as described by the manufacturer. The PCR reactions proceeded in an ABI PRISM 7700 Sequence Detector (PE Applied Biosystems, USA). To obtain a standard curve using normal BM-MNC cDNA, we generated PCR products using the other primer set for each gene. These PCR products were serially diluted and again amplified with the respective Taqman primer set and probe. All quantitative PCR reactions were performed in triplicate, and the mean of the three reactions was considered as a representative value for each sample. The expression levels of DNMT1, 3a and 3b were normalized to the endogenous control, GAPDH, as described above. Differences between groups were analyzed using the nonparametric Mann-Whitney test. Figure 1a shows that the expression levels of DNMT1 and DNMT3b mRNA among the cell lines were significantly higher than those among controls. In MDS, the expression level of DNMT1 mRNA alone was significantly higher than in controls. However, when the histoneH4 gene was the internal standard, which would compensate for changes in gene expression during the cell cycle, the difference in DNMT1 expression between MDS and controls was no longer significant, whereas that in DNMT1 and DNMT3b between cell lines and controls remained (data not shown). The MSP method revealed methylation of the p15 INK4B gene in five of 15 cell lines and in BM samples from nine of 24 patients with MDS. In BM samples obtained from MDS, 0% of RA and RARS, 20% of RAEB, 80% of RAEB-T, 33% of CMML, 100% of sAML patients had methylated-p15 gene. We evaluated the correlation between methylation status of the p15 INK4B gene and expression levels of DNMT1, 3a and 3b mRNA. The expression levels of DNMT mRNAs between p15-methylated and p15-unmethylated groups did not significantly differ among cell lines (data not shown) or among cells from patients with MDS ( Figure 1b) .
Mizuno et al 9 reported that DNMT1, 3a and 3b are significantly overexpressed in AML. They also demonstrated that p15-methylated patients with AML tended to express higher levels of DNMTs. On the contrary, the present study found no correlation between p15 INK4B gene methylation and DNMT expression levels in MDS. Besides, although aberrant methylation tends to be more frequent among patients with advanced MDS, 1 the FAB subtype of such patients did not correlate with DNMT expression levels. However, the number of patients was too small for statistical evaluation (data not shown). These results suggest that DNMTs play different roles in tumorigenesis in MDS and AML. Our results suggest that other mechanisms, such as chromatin remodeling in promoter region of p15 INK4B gene or methylation-dependence from cell division, 10 should be considered in the regulation of p15 INK4B gene methylation in MDS.
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